Cargando...
Cardiac Myosin Activation for the Treatment of Systolic Heart Failure
Left ventricular systolic dysfunction is the hallmark pathology in heart failure with reduced ejection fraction. Increasing left ventricular contractility with beta-adrenergic receptor agonists, phosphodiesterase-3 inhibitors, or levosimendan has failed to improve clinical outcomes and, in some situ...
Gardado en:
| Publicado en: | J Cardiovasc Pharmacol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7779665/ https://ncbi.nlm.nih.gov/pubmed/33165138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000929 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|